Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoMEX:4519N 97 Return-on-Tangible-Equity is 23.83% as of Jun. 2026, which is 9% above its 10-year median of 21.93. GuruFocus rates MEX:4519N with a GF Score™ of 97/100 and a GF Value™ of MXN924.39. The stock has 1 warning sign investors should review. Among 900 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 82.78% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Chugai Pharmaceutical Co's annualized net income for the quarter that ended in Jun. 2026 was MXN50,503 Mil. Chugai Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Jun. 2026 was MXN211,891 Mil. Therefore, Chugai Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 23.83%.
The historical rank and industry rank for Chugai Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
MEX:4519N'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.65 Med: 21.93 Max: 29.19
Current: 24.56
During the past 13 years, Chugai Pharmaceutical Co's highest Return-on-Tangible-Equity was 29.19%. The lowest was 8.65%. And the median was 21.93%.
MEX:4519N's Return-on-Tangible-Equity is ranked better than 82.78% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.895
vs MEX:4519N: 24.56
Chugai Pharmaceutical Co (MEX:4519N) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Chugai Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Chugai Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Chugai Pharmaceutical Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co Return-on-Tangible-Equity Chart
MEX:4519N vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 23.83% mean?
Chugai Pharmaceutical Co (MEX:4519N) has a Return-on-Tangible-Equity of 23.83% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chugai Pharmaceutical Co and its competitors. This is near median its historical median of 21.93. Over the past decade, Chugai Pharmaceutical Co's Return-on-Tangible-Equity has ranged from 8.65 to 29.19. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #155 out of 900 companies in the Drug Manufacturers industry, placing it in the top 17.2%.
Is Chugai Pharmaceutical Co's Return-on-Tangible-Equity too high?
Chugai Pharmaceutical Co's current Return-on-Tangible-Equity of 23.83% is near median its 10-year median of 21.93. Over the past 10 years, this metric has ranged from a low of 8.65 to a high of 29.19. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Chugai Pharmaceutical Co's value of 23.83% is 201.8% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #155 out of 900 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #155 out of 900 companies for Return-on-Tangible-Equity. This places Chugai Pharmaceutical Co in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Chugai Pharmaceutical Co's value of 23.83% is 201.8% above this benchmark. Historically, Chugai Pharmaceutical Co's own Return-on-Tangible-Equity has ranged from 8.65 to 29.19 over the past decade. While the company's 10-year median is 21.93 vs. the industry median of 7.90, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Return-on-Tangible-Equity of 23.83% is 201.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Return-on-Tangible-Equity is 23.83%, which is near median its own 10-year median of 21.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Chugai Pharmaceutical Co (MEX:4519N) has a current Return-on-Tangible-Equity of 23.83%. The stock's GF Value™ is MXN924.39, compared to a current price of MXN825.61 — trading 10.7% below its estimated fair value. The current Return-on-Tangible-Equity is 23.83%, which is near median its 10-year median of 21.93 and 201.8% above the Drug Manufacturers industry median of 7.90. Chugai Pharmaceutical Co's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Chugai Pharmaceutical Co (MEX:4519N), the current Return-on-Tangible-Equity is 23.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (MEX:4519N) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of MXN825.61 is trading 10.7% below its estimated GF Value™ of MXN924.39.
Key valuation signals for MEX:4519N:
Return-on-Tangible-Equity: 23.83% (near median its 10-year median of 21.93)
GF Value™: MXN924.39 vs. price of MXN825.61 (10.7% below fair value)
Industry Position: 201.8% above the Drug Manufacturers median (#155 of 900)
No single metric tells the full story. See the MEX:4519N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
97GF Score
Get the complete analysis for MEX:4519N
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4519N has been successfully added to your 
